SUBSCRIBE

Adalimumab biosimilar FKB327 causes less pain than originator

 Posted 09/04/2021

Fujifilm Kyowa Kirin Biologics’ adalimumab biosimilar FKB327 has been found to cause less injection-site pain compared to the reference product, according to...

more
New partnerships for Cipla and Samsung Bioepis Pharma News | Posted 09/04/2021
Biosimilars regulation, clinical trials, approv... Biosimilars/Research | Posted 09/04/2021
FDA accepts application for adalimumab biosimil... Biosimilars/News | Posted 09/04/2021
Improved regulation favouring copy biologicals... Reports | Posted 09/04/2021
Biosimilars of ustekinumab Biosimilars/General | Posted 09/04/2021
Dispensing branded drugs costs Medicare over a... Generics/Research | Posted 09/04/2021
China improves generics injection consistency e... Policies & Legislation | Posted 09/04/2021
Etanercept biosimilar injection pen, YLB113, co... Biosimilars/Research | Posted 02/04/2021
Pfizer sells Chinese copy biologicals plant to... Pharma News | Posted 02/04/2021
Technological approaches to drug repurposing fo... Generics/Research | Posted 02/04/2021
Samsung Bioepis and Eden Biologics announce new... Biosimilars/Research | Posted 02/04/2021
Patent expiries may drive development of copy b... Reports | Posted 02/04/2021
Australian and Indian approval for teriparatide... Biosimilars/News | Posted 02/04/2021
Biosimilars of aflibercept Biosimilars/General | Posted 02/04/2021
EMA recommends approval of abiraterone and thio... Generics/News | Posted 02/04/2021
Biosimilars in Europe: prescriber survey Biosimilars/Research | Posted 26/03/2021
Argentina approves bevacizumab similar biologic... Biosimilars/News | Posted 26/03/2021
Cancer driving the need for copy biologicals in... Reports | Posted 26/03/2021
EC approval for insulin aspart biosimilar Kixelle Biosimilars/News | Posted 26/03/2021
Public health impact of using biosimilars and r... Biosimilars/Research | Posted 26/03/2021
Drug regulators need to evolve with biosimilars Reports | Posted 26/03/2021
Italy simplifies over-the-counter generics pric... Policies & Legislation | Posted 26/03/2021
Teva and Sandoz launch new generics Generics/News | Posted 26/03/2021
Pelmeg developed with aid of regulatory reform Biosimilars/Research | Posted 19/03/2021
IVM releases toolbox on how to switch patients... Biosimilars/General | Posted 19/03/2021
The state of play for copy biologicals in China Reports | Posted 19/03/2021
Confidence in clinical evidence and switching d... Reports | Posted 19/03/2021
16704526_l
EMA recommends approval of fourth COVID-19 vaccine Generics/News | Posted 19/03/2021
19646665_l
Knowledge and perceptions about naming biosimil... Biosimilars/Research | Posted 19/03/2021
Debate about generic versus brand-name drugs fo... Generics/Research | Posted 19/03/2021
EC approves adalimumab biosimilar Yuflyma Biosimilars/News | Posted 19/03/2021
Approaches to naming and labelling of biosimilars Biosimilars/Research | Posted 12/03/2021
EMA recommends approval of four bevacizumab bio... Biosimilars/News | Posted 12/03/2021
Australia launches new medicines road map and s... Policies & Legislation | Posted 12/03/2021
Targets and incentives to encourage use of bios... Reports | Posted 12/03/2021
China accepts IND application for daratumumab c... Biosimilars/News | Posted 12/03/2021
Sandoz acquires GSK antibiotics and Perrigo gen... Pharma News | Posted 12/03/2021
Infliximab biosimilars for IBD patients: experi... Biosimilars/Research | Posted 12/03/2021
Posaconazole, silodosin and droxidopa generics... Generics/News | Posted 12/03/2021
Interchangeability V18K30
Different approaches to the interchangeability... Biosimilars/Research | Posted 05/03/2021
Latest launches for adalimumab biosimilars in C... Biosimilars/News | Posted 05/03/2021
Biocon Biologics partners to improve global acc... Pharma News | Posted 05/03/2021
Biosimilar patent litigation trends in the US Biosimilars/General | Posted 05/03/2021
Efficacy and safety of interferon beta-1a (Reci... Biosimilars/Research | Posted 05/03/2021
The role of authorized generics in improving ac... Generics/Research | Posted 05/03/2021
Education for biosimilars in Europe and the US Reports | Posted 05/03/2021
Opportunities for generics with Korean patent e... Generics/General | Posted 05/03/2021
Access! AAM Annual Meeting 2021 Conferences | Posted 05/03/2021
Collaboration between regulatory authorities fo... Biosimilars/Research | Posted 26/02/2021
more

NON-BIOLOGICAL COMPLEX DRUGS

FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...

more


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 04/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015
more

Country Focus

All countries

Sign up today to receive weekly news on the latest developments in generic and biosimilar medicines!

Generics News Research General

more

Biosimilars News Research General

more

More editorial sections